GlassScriptPhysician profile
Jacquelyn S Meinhardt
NPI 1215229943
$548.59
in general payments reported to CMS, 2019-2025
11 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $190 · 2024: $115 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $190.42 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.85 | 2023-2025 | Xifaxan, Trulance |
| Acella Pharmaceuticals, LLC | $36.81 | 2025 | NP Thyroid 60 |
| Neurocrine Biosciences, INC. | $33.96 | 2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.61 | 2025 | Caplyta |
| Corium, LLC | $31.18 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $30.26 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $26.21 | 2025 | Cuvitru |
| Invivyd INC | $24.01 | 2025 | Pemgarda |
| Supernus Pharmaceuticals, INC. | $23.67 | 2023 | Qelbree |
| Noven Therapeutics, LLC | $15.61 | 2025 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Meinhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.